论文部分内容阅读
目的:探讨针对支气管哮喘患者,选择孟鲁司特钠+布地奈德完成治疗后的临床效果。方法:选取我院2012年05月-2014年05月支气管哮喘患者80例。通过抽签法将所有支气管哮喘患者分为D1组(观察组40例)与D2组(对照组40例)。D2组:常规治疗(抗感染、化痰以及吸氧等)+布地奈德治疗;D1组:常规治疗+孟鲁司特钠+布地奈德给予临床治疗;两组支气管哮喘患者完成治疗后,对比两组患者肺功能改善的程度以及临床治疗总有效率。结果:在临床治疗总有效率方面,D1组支气管哮喘患者高于D2组患者尤为显著(P<0.05);同治疗前进行比较,两组支气管哮喘患者在FEV1以及PEF等指标方面,表现为显著的改善(P<0.05)。组间比较表现出差异(P<0.05)。在临床出现不良反应方面,D1组支气管哮喘患者与D2组患者未表现出显著差异(P>0.05)。结论:针对支气管哮喘患者,选择孟鲁司特钠+布地奈德给予临床治疗,患者的肺功能表现为显著的改善,临床疗效得到了有效促进。
Objective: To investigate the clinical effect of montelukast and budesonide in the treatment of patients with bronchial asthma. Methods: 80 patients with bronchial asthma were selected from May 2012 to May 2014 in our hospital. All bronchial asthma patients were divided into D1 group (observation group 40 cases) and D2 group (control group 40 cases) by lottery method. D2 group: conventional treatment (anti-infection, phlegm and oxygen, etc.) + budesonide treatment; D1 group: conventional treatment + montelukast sodium + budesonide clinical treatment; two groups of patients with bronchial asthma after treatment, The degree of pulmonary function improvement and the total effective rate of clinical treatment in both groups were compared. Results: The total effective rate of clinical treatment in patients with bronchial asthma in group D1 was significantly higher than that in group D2 (P <0.05). Compared with those in group before treatment, the two groups of patients with bronchial asthma showed significant FEV1 and PEF Improvement (P <0.05). Differences between the groups showed differences (P <0.05). There was no significant difference in the clinical adverse reactions between patients with D1 and patients of bronchial asthma (P> 0.05). Conclusion: For patients with bronchial asthma, the choice of montelukast sodium + budesonide for clinical treatment, the patient’s pulmonary function was significantly improved, the clinical efficacy has been effectively promoted.